Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

What if your doctor could, when you turn 65, order a test that predicts whether you are going to develop Alzheimer’s dementia in your 70s or 80s? And what if – in case the test comes back ...

Eli Lilly and Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group ...

The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment  a thumbs down, Europe’s Committee for Medicinal Products ...

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug, Kisunla, one step closer to European market entry.

An expert committee recommended that the drug be offered to a narrow group of patients with early-stage Alzheimer’s ...

Roche is focusing on early diagnosis of Alzheimer's disease and will soon release its first blood-based biomarker for the ...

The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side ...

UCSF researchers found the cancer drugs letrozole and irinotecan may reverse Alzheimer's effects, reducing tau protein clumps ...